Skip to content

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07374861
Acronym
BEMPENET
Enrollment
1500
Registered
2026-01-29
Start date
2025-11-04
Completion date
2028-12-31
Last updated
2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Brief summary

Evaluation of adherence, persistence, and efficacy of treatment with Bempedoic acid in a real-life Italian population.

Interventions

DRUGBempedoic acid

film-coated tablets

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients under Bempedoic acid treatment

Exclusion criteria

* Age \< 18 years o \> 80 years * Patients who refuse to participate and to sign informed consent

Design outcomes

Primary

MeasureTime frameDescription
Description of adherence to treatment with Bempedoic acid in a real-life Italian population6-12-24-36 monthsAdherence will be assessed in terms of Medical Possession Ratio (MPR), which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself.
Description of efficacy of treatment with Bempedoic acid in a real-life Italian population6-12-24-36 monthsEfficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value).
Description of persistence to treatment with Bempedoic acid in a real-life Italian population6-12-24-36 monthsPersistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment.

Secondary

MeasureTime frameDescription
Description of safety of treatment with Bempedoic acid in a real-life Italian population6-12-24-36 monthsSafety will be evaluated in terms of adverse reactions or intolerance to the drug.

Countries

Italy

Contacts

CONTACTPasquale Perrone Filardi
fpperron@unina.it+39081/7462224

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026